Treatment of Atopic Dermatıtıs in Children

Yıl 2017, Cilt: 9 Sayı: 2, 103 - 108, 15.03.2017

Uzm. Dr. Gizem Atakul

Öz

Abstract

Atopic dermatitis is a common chronic inflammatory skin disease associated with cutaneous hyperreactivity to various environmental triggers. The aim of the treatment should be focused on suppression of chronic inflammation and control of acute exacerbations. Basic therapy of atopic dermatitis should comprise optimal skin care with regular use of emollients, and avoidance from specific triggering factors. Topical treatment options like topical corticosteroids and calcineurin in hibitors are the milestones of the severe atopic dermatitis. The risk of adverse effects induced by topical corticosteroids could be reduced by proactive treatment modality. Topical calcineurin inhibitors allow a steroid-free anti-inflammatory topical treatment with a safe application on sensitive skin areas. Advanced treatment options should be administered as stepwise treatment, depending on the severity of the disease. In severe casesof atopic dermatitis, systemic oral steroids, immunosuppressant drugs, wet wrap, phototherapy and allergen immunotherapy can be administered. Systemic antibiotic treatment is indicated for widespread secondary bacterial skin infections. The management of atopic dermatitis should be individualized according to the severity of the disease and patients’ clinical conditions.

Anahtar Kelimeler

Child, atopic dermatitis, treatment

Çocuklarda Atopik Dermatit Tedavisi

Öz

Öz

Atopik dermatit çeşitli çevresel tetikleyicilerin ortaya çıkardığı aşırı cilt duyarlılığı ile ilişkili kronik enflamatuvar bir deri hastalığıdır. Tedavinin amacı kronik enflamasyonun baskılanması ve akut alevlenmelerin kontrol altına alınmasıdır. Atopik dermatitin temel tedavisi düzenli nemlendirici kullanımı ile uygun cilt bakımının sağlanması ve belirli tetikleyici etkenlerden uzak durulmasını içerir. Topikal kortikosteroidler ve kalsinörin inhibitörleri ağır atopik dermatit tedavisinin köşe taşını oluşturur. Topikal kortikosteroidler ile artan yan etki riski proaktif tedavi uygulaması ile azaltılabilir. Topikal kalsinörin inhibitörleri hassas cilt bölgelerine güvenle uygulanabilen steroid içermeyen topikal antienflamatuvar ilaçlardır. İleri tedavi seçenekleri, hastalığın ağırlığına bağlı olarak, basamak tedavisi şeklinde uygulanmalıdır. Ağıratopik dermatitli olgularda, sistemik tedavide oral steroidler, bağışıklık sistemini baskılayan ilaçlar, ıslak pansuman, fototerapi ve alerjen immunoterapisi uygulanabilir.Sistemik antibiyotik tedavisi yaygın ikincil bakteriyel cilt infeksiyonlarında kullanılmalıdır. Atopik dermatit tedavisi hastalığın ağırlığına ve hastanın klinik durumuna göre bireyselleştirilmelidir.

Anahtar Kelimeler

Çocuk, atopik dermatit, tedavi

Kaynakça

• Kaynaklar 1. Severity scoring of atopic dermatitis: the SCORAD index. Con-sensus Report of the European Task Force on Atopic Derma-titis. Dermatology. 1993;186:23-31. 2. Nathaniel A. Slater, BA, Dean S. Morrell, Systemic therapyof childhood atopic dermatitis. Clinics in Dermatology 2015;33: 289–99. 3. Eliza R. Notaro,Robert Sidbury. Systemic Agents for Severe Ato-pic Dermatitis in Children. Pediatr Drugs 2015; 17: 449–57. 4. Carsten Flohr, Alan D. Irvine. Systemic therapies for severeatopic dermatitis in children and adults J Allergy Clin Immu-nol 2013;132(3): 774-7. 5. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Tre-atment of Staphylococcus aureus colonization in atopic derma-titis decreases disease severity. Pediatrics 2009;123:808-14. 6. Wollenberg A, Wetzel S, Burgdorf WH, Haas J. Viral infectionsin atopic dermatitis: pathogenic aspects and clinical manage-ment. J Allergy Clin Immunol. 2003 Oct;112:667-74. 7. Grimalt R, Mengeaud V, Cambazard F. The steroid-sparing ef-fect of an emollient therapy in infants with atopic dermatitis:a randomized controlled study. Dermatology. 2007;214:61-7. 8. Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van HO, Al-legra F, Parker CA. Twice weekly fluticasone propionate ad-ded to emollient maintenance treatment to reduce risk of re-lapse in atopic dermatitis: randomised, double blind, paral-lel group study. BMJ. 2003 Jun 21;326:1367. 9. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gel-metti C, Gieler U, Lipozencic J, Luger T, et al. Guidelines fortreatment of atopic eczema (atopic dermatitis) part I. J EurAcad Dermatol Venereol. 2012 Aug;26:1045-60. 10.Wollenberg A, Bieber T. Proactive therapy of atopic derma-titis--an emerging concept. Allergy. 2009 Feb;64:276-8. 11. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Bogunie-wicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, et al. Di-agnosis and treatment of atopic dermatitis in children andadults: European Academy of Allergology and Clinical Im-munology/American Academy of Allergy, Asthma and Immu-nology/PRACTALL Consensus Report. Allergy. 2006Aug;61:969-87. 12. Charman C, Williams H. The use of corticosteroids and cor-ticosteroid phobia in atopic dermatitis. Clin Dermatol. 2003 May; 21: 193 -200. 13. Chen SL, Yan J, Wang FS. Two topical calcineurin inhibitorsfor the treatment of atopic dermatitis in pediatric patients: ameta-analysis of randomized clinical trials. J Dermatolog Tre-at. 2010 May;21:144-56. 14. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G,Zagula M, Ortonne JP. The new topical ascomycin derivati-ve SDZ ASM 981 does not induce skin atrophy when appliedto normal skin for 4 weeks: a randomized, double-blind con-trolled study. Br J Dermatol. 2001 Mar;144:507-13. 15. Thaci D, Salgo R. Malignancy concerns of topical calcineu-rin inhibitors for atopic dermatitis: facts and controversies.Clin Dermatol. 2010 Jan;28:52-6. 16. Lubbe J, Pournaras CC, Saurat JH. Eczema herpeticum du-ring treatment of atopic dermatitis with 0.1% tacrolimus oint-ment. Dermatology. 2000;201:249-51. 17. Wetzel S, Wollenberg A. Eczema molluscatum in tacrolimus trea-ted atopic dermatitis. Eur J Dermatol. 2004 Jan;14:73-4. 18. Devillers AC, Oranje AP. Efficacy and safety of 'wet-wrap'dressings as an intervention treatment in children with seve-re and/or refractory atopic dermatitis: a critical review of theliterature. Br J Dermatol. 2006 Apr;154:579-85. 19. Eichenfield LF, Ho V, Matsunaga J, Leclerc P, Paul C, Ha-nifin JM. Blood concentrations, tolerability and efficacy of pi-mecrolimus cream 1% in Japanese infants and children withatopic dermatitis. J Dermatol. 2007 Apr;34:231-6. 20. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H,Harada S. Addition of fexofenadine to a topical corticostero-id reduces the pruritus associated with atopic dermatitis in a1-week randomized, multicentre, double-blind, placebo-con-trolled, parallel-group study. Br J Dermatol. 2003Jun;148:1212-21. 21. Brockow K, Grabenhorst P, Abeck D, Traupe B, Ring J, Hop-pe U, Wolf F. Effect of gentian violet, corticosteroid and tarpreparations in Staphylococcus-aureus-colonized atopic ec-zema. Dermatology. 1999;199:231-6. 22. Birnie AJ, Bath-Hextall FJ, Ravenscroft JC, Williams HC. In-terventions to reduce Staphylococcus aureus in the management of atopic eczema. Cochrane Database Syst Rev.2008;CD003871. 23. Legat FJ, Wolf P. Cutaneous sensory nerves: mediators of pho-totherapeutic effects? Front Biosci. 2009;14:4921-31. 24. Darsow U, Forer I, Ring J. Allergen-specific immunotherapy inatopic eczema. Curr Allergy Asthma Rep. 2011 Aug;11:277-83. 25. Forte WCN, Sumita JM, Rodrigues AG, Liuson D, Tanaka E.Rebound phenomenon to systemic corticosteroid in atopic der-matitis. Allergol Immunopathol (Madr). 2005;33:307-11. 26. Berth-Jones J, Finlay AY, Zaki I, et al. Cyclosporine in seve-re childhood atopic dermatitis: A multicenter study. J Am AcadDermatol. 1996;34:1016-21. 27. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatmentof patients with atopic eczema: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21:606-9. 28. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gel-metti C, Gieler U, Lipozencic J, Luger T, et al. Guidelines fortreatment of atopic eczema (atopic dermatitis) Part II. J EurAcad Dermatol Venereol. 2012 Sep;26:1176-93. 29. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Enteric-coated mycophe-nolate sodium versus cyclosporin A as long-term treatment inadult patients with severe atopic dermatitis: a randomized con-trolled trial. J Am Acad Dermatol. 2011;64(6):1074–84. 30. Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mo-fetil for severe childhood atopic dermatitis: Experience in 14patients. Br J Dermatol. 2007;157:127-32. 31. Deo M, Yung A, Hill S, Rademaker M. Methotrexate for tre-atment of atopic dermatitis in children and adolescents. IntJ Dermatol. 2014;53(8):1037–41. 32. Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M,Ruzicka T, Brehler R, Wolf H, et al. Usefulness of specific im-munotherapy in patients with atopic dermatitis and allergicsensitization to house dust mites: a multi-centre, randomized,dose-response study. Allergy. 2006 Feb;61:202-5. 33. Glover MT, Atherton DJ. A double-blind controlled trial ofhyposensitization to Dermatophagoides pteronyssinus inchildren with atopic eczema. Clin Exp Allergy. 1992Apr;22:440-6. 34. Mastrandrea F, Serio G, Minelli M, Minardi A, Scarcia G,Coradduzza G, Parmiani S. Specific sublingual immunothe-rapy in atopic dermatitis. Results of a 6-year follow-up of 35consecutive patients. Allergol Immunopathol (Madr ). 2000Mar;28:54-62. 35. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lom-bardo F, Canonica GW, Passalacqua G. Sublingual immunot-herapy in mite-sensitized children with atopic dermatitis: a ran-domized, double-blind, placebo-controlled study. J Allergy ClinImmunol. 2007 Jul;120:164-70. 36. Galli E, Chini L, Nardi S, Benincori N, Panei P, Fraioli G,Moschese V, Rossi P. Use of a specific oral hyposensitizati-on therapy to Dermatophagoides pteronyssinus in children withatopic dermatitis. Allergol Immunopathol (Madr ). 1994Jan;22:18-22. 37. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy ofallergen-specific immunotherapy for atopic dermatitis: a syste-matic review and meta-analysis of randomized controlled tri-als. J Allergy Clin Immunol 2013;132:110–7.